Necitumumab
Recombinant human monoclonal antibody
- US DailyMed: Necitumumab
administration
- L01FE03 (WHO)
- 906805-06-9 N
- DB09559 Y
- none
- 2BT4C47RUI
- D10018 N
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[3] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[4][5][6] It was counterproductive in non-squamous non-small-cell lung carcinoma.[6][7]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28.
- ^ "Necitumumab". Approved Drugs. U.S. Food and Drug Administration. Archived from the original on 2017-01-11. Retrieved 2019-12-16.
- ^ a b "Portrazza: Highlights of Prescribing Information" (PDF). www.accessdata.fda.gov. 2015. Retrieved 2019-09-28.
- ^ Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e